Shots:

• The P-III DAPA-HF study involves assessing of Farxiga (10mg- qd) vs PBO in patients with heart failure and reduced ejection fraction (HFrEF) (LVEF ≤ 40%)- with/without type-2 diabetes on the addition to SOC including ACE inhibitors- ARB- MRAs- beta-blockers and neprilysin inhibitors
• The P-III DAPA-HF study resulted in meeting its 1EPs i.e- reduction in cardiovascular death or worsening of heart failure
• Farxiga is an oral SGLT2 inhibitor- indicated as both monothx. and combination therapy to improve glycemic control- reduction in weight & blood pressure as an adjunct to diet and exercise in patients with T2D- also being studied in patients with HF in DELIVER and DETERMINE (HFrEF and HFpEF) trials respectively

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca